It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glioblastoma contains a rare population of self-renewing brain tumor stem cells (BTSCs) which are endowed with properties to proliferate, spur the growth of new tumors, and at the same time, evade ionizing radiation (IR) and chemotherapy. However, the drivers of BTSC resistance to therapy remain unknown. The cytokine receptor for oncostatin M (OSMR) regulates BTSC proliferation and glioblastoma tumorigenesis. Here, we report our discovery of a mitochondrial OSMR that confers resistance to IR via regulation of oxidative phosphorylation, independent of its role in cell proliferation. Mechanistically, OSMR is targeted to the mitochondrial matrix via the presequence translocase-associated motor complex components, mtHSP70 and TIM44. OSMR interacts with NADH ubiquinone oxidoreductase 1/2 (NDUFS1/2) of complex I and promotes mitochondrial respiration. Deletion of OSMR impairs spare respiratory capacity, increases reactive oxygen species, and sensitizes BTSCs to IR-induced cell death. Importantly, suppression of OSMR improves glioblastoma response to IR and prolongs lifespan.
The suppression of the receptor for oncostatin M (OSMR) can prevent glioblastoma cell growth. Here, the authors demonstrate a role for OSMR in modulating glioma stem cell respiration and its impact on resistance to ionizing radiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774)
2 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); Montreal Neurological Institute, Integrated program in Neuroscience, Montréal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639)
3 Pharmacology and Ophthalmology, Université de Montréal, CHU Sainte-Justine, Departments of Pediatrics, Montréal, Canada (GRID:grid.416102.0); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
4 Pharmacology and Ophthalmology, Université de Montréal, CHU Sainte-Justine, Departments of Pediatrics, Montréal, Canada (GRID:grid.14709.3b); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
5 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); McGill University, 3640 Rue University, Department of Human Genetics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
6 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); Montreal Neurological Institute, Integrated program in Neuroscience, Montréal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639); McGill University, Gerald Bronfman Department of Oncology and Division of Experimental Medicine, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)